Annovis Bio, Inc.

NYSE:ANVS

4.37 (USD) • At close December 20, 2024
Bedrijfsnaam Annovis Bio, Inc.
Symbool ANVS
Munteenheid USD
Prijs 4.37
Beurswaarde 60,293,764
Dividendpercentage 0%
52-weken bereik 4.31 - 22.49
Industrie Biotechnology
Sector Healthcare
CEO Dr. Maria L. Maccecchini Ph.D.
Website https://www.annovisbio.com

An error occurred while fetching data.

Over Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's

Vergelijkbare Aandelen

Sonendo, Inc. logo

Sonendo, Inc.

SONX

1.92 USD

Vapotherm, Inc. logo

Vapotherm, Inc.

VAPO

2.17 USD

Rafael Holdings, Inc. logo

Rafael Holdings, Inc.

RFL

1.95 USD

Enzo Biochem, Inc. logo

Enzo Biochem, Inc.

ENZ

0.763 USD

Ambrx Biopharma Inc. logo

Ambrx Biopharma Inc.

AMAM

28 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)